NCT06927310招募中3 期
A Multicenter, Randomized, Open-Label, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Inpegsomatropin Injection, s.c Once a Week, Compared With Recombinant Human Growth Hormone (rhGH) Injection in Children With Idiopathic Short Stature (ISS).
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 38
- 主要终点
- Growth velocity (HV, cm/year).
研究概览
简要总结
This is a multicenter, randomized, open-label, active-controlled Phase III clinical trial to evaluate the efficacy and safety of Inpegsomatropin injection，once a week，compared with recombinant human growth hormone (rhGH) in children with idiopathic short stature (ISS). It plans to enroll 300 children with ISS, who will be randomized , stratified by gender and age, and assigned to either the experimental group or the positive controlled group. Each participant will undergo a screening period (up to 12 weeks), a treatment period (52 weeks), and a post-treatment follow-up period (5 weeks). And the safety and efficacy will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Prepubertal children: boys aged ≥3 years and <11 years at screening with testicular volume <4 mL; girls aged ≥3 years and <10 years at screening with breast development at Tanner Stage I, i.e., no palpable breast glandular tissue.
- •Compared to chronological age, bone age is advanced by no more than 1 year or delayed by no more than 2 years (i.e., -2 years ≤ bone age - chronological age ≤ 1 year).
- •Height at screening is below -2 standard deviations (SD) from the mean for age and sex, with height reference to Appendix
- •Body mass index (BMI) is within the 5th to 95th percentile for age and sex of healthy children, with reference to Appendix
- •Peak GH level ≥10.0 ng/ml in at least one GH stimulation test.
- •No prior systemic pharmacological treatment for growth promotion (continuous use ≥1 month), including but not limited to growth hormone, insulin-like growth factor 1 (IGF-1), etc.
- •The legal guardian understands and signs the informed consent form. If the participants is ≥8 years old, they must also sign the informed consent form. For participants under 8 years old who are able to express their consent, their assent should be clearly documented.
排除标准
- •Individuals with closed epiphyses;
- •Other types of growth and developmental abnormalities, including confirmed or highly suspected growth hormone deficiency (GHD), Noonan syndrome, Prader-Willi syndrome, Russell-Silver syndrome, Turner syndrome, small for gestational age, short stature due to SHOX gene abnormalities, growth delay due to malnutrition, growth delay due to hypothyroidism, and other short statures with a clear etiology; genetic testing results must be obtained before randomization to exclude short stature caused by definite genetic abnormalities;
- •Individuals who have participated in any other clinical trial within 3 months prior to screening and have received pharmacological or non-pharmacological interventions;
- •Individuals who received inhaled corticosteroids for more than 2 consecutive weeks, or oral or intravenous corticosteroids for more than 1 consecutive week, within the 3 months prior to screening;
- •Individuals who are currently receiving or require long-term treatment with other therapies that may affect growth, including but not limited to methylphenidate, sex hormones, gonadotropin-releasing hormone analogs, aromatase inhibitors, anabolic agents, insulin, etc.;
- •Individuals with abnormal liver or kidney function at screening (ALT > 1.5 times the upper limit of normal, Cr > upper limit of normal);
- •Individuals diagnosed with diabetes mellitus, or with fasting blood glucose ≥6.1 mmol/L on two consecutive occasions;
- •Individuals with chronic infectious diseases, such as chronic hepatitis B;
- •Individuals with systemic chronic diseases, such as moderate to severe anemia, malnutrition, hypothyroidism, chronic kidney disease, cardiovascular diseases (e.g., dilated cardiomyopathy, etc.), psychiatric and psychological disorders, or those with congenital anomalies requiring clinical intervention as determined by the investigator;
- •Individuals with congenital skeletal abnormalities, or those with scoliosis exceeding 15°, limping, or a history of slipped capital femoral epiphysis;
- •Individuals with a history of increased intracranial pressure;
- •Individuals with a history of malignancy or currently having active malignancy, including intracranial tumors;
- •Individuals with severe allergic constitutions, or known allergies to growth hormone or its excipients;
- •Individuals with any other disease that the investigator deems may endanger the subject's safety or compromise compliance with the study protocol.
研究组 & 干预措施
Inpegsomatropin group
Experimental
干预措施: Inpegsomatropin Injection (Drug)
rhGH group
Active Comparator
干预措施: Recombinant Human Growth Hormone Injection (Drug)
结局指标
主要结局
Growth velocity (HV, cm/year).
时间窗: Week 52
次要结局
- Change in height standard deviation score from baseline (△HT SDS)(From baseline to all follow-up time points at Week 52)
- Change in growth velocity from baseline (△HV)(From baseline to all follow-up time points at Week 52)
- Change in insulin-like growth factor 1 standard deviation score from baseline (△IGF-1 SDS)(From baseline to all follow-up time points at Week 52)
- The ratio of the change in bone age to the change in chronological age (△BA/△CA)(From baseline to all follow-up time points at Week 52)
研究者
研究点 (38)
Loading locations...
相似试验
已完成
3 期
A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast CancerBreast CancerNCT00109239Genentech, Inc.
进行中（未招募）
3 期
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCLPeripheral T Cell LymphomaNCT04668690CSPC ZhongQi Pharmaceutical Technology Co., Ltd.193
终止
3 期
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder CancerBladder NeoplasmNeoplasm Recurrence, LocalTransitional Cell, CarcinomaCarcinoma in SituMycobacteriumNCT01200992Bioniche Life Sciences Inc.84
招募中
3 期
Neoadjuvant SNF Precision Therapy Phase IIINCT06913777Fudan University404
进行中（未招募）
3 期
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical CancerCervical CancerNCT04906993Jiangsu HengRui Medicine Co., Ltd.443